Skip to content

BJCP article: Analysis examines safety of antidepressant use during pregnancy

Use of fluoxetine – the most commonly prescribed antidepressant – during pregnancy is linked with a slightly increased risk of malformations in infants, according to a recent analysis of published studies.

In the analysis of 16 studies, infants exposed to fluoxetine during the first trimester had an 18% increased relative risk of major malformations and a 36% increased relative risk of cardiovascular malformations. There were no significant observations of other system-specific malformations in the nervous system, eye, urogenital system, digestive system, respiratory system, or musculoskeletal system.

The findings are published in the British Journal of Clinical Pharmacology.

Similar research was published at an earlier time in the British Journal of Clinical Pharmacology

Latest news & activity

Press releases

CERSI-PGx is expanding its free pharmacogenomics eLearning offer with the launch of new modules.

Grant

Applications are now open for the BPS Education Grant.

The grant awards up to £2,500 to support the creation or development of educational tools and…

Governance

Applications/nominations extended to 28 October 2026